An Innovative Chronic Dialysis Catheter With Patented Triple Arterial
VANCOUVER, March 13 /CNW/ - Angiotech Pharmaceuticals, Inc.
(NASDAQ: ANPI, TSX: ANP) today announced that it will introduce and exhibit
its innovative HemoStream(TM) chronic dialysis catheter at the 2008 Society of
Interventional Radiology (SIR) Annual Scientific Meeting to be held in
Washington, DC from March 15-18, 2008.
"It's exciting to participate at SIR and showcase the addition of another
'best-in-class' device offered by Angiotech. We also anticipate that the
HemoStream(TM) could be a great candidate for our combination drug-device
technologies, such as Angiotech's innovative 5-FU anti-infective platform,"
said George Leondis, General Manager, Angiotech Interventional.
Incidences of End Stage Renal Disease (ESRD) requiring dialysis are a
rapidly growing challenge in healthcare worldwide. When kidneys fail, function
of the kidneys can be partially replaced using a process called hemodialysis.
Hemodialysis involves drawing blood out of the body, filtering it through a
large machine and then returning filtered blood back to the body. Chronic
dialysis catheters, such as HemoStream(TM), are used as long term vascular
access for hemodialysis. HemoStream may also be used as a temporary access
while more permanent options mature or become ready for use, such as a
surgically created AV fistula.
A dialysis catheter, such as HemoStream(TM), is used for vascular access
and is a vital connection between the patient and the hemodialysis unit. When
kidneys fail, the function of the kidneys can be partially replaced using a
process called hemodialysis. Hemodialysis involves drawing blood out of the
body, filtering it through a large machine that draws off the impurities and
then returning the filtered blood to the body. When patients are placed on
hemodialysis, they will require placement of a catheter into a large vein
which is then connected to a hemodialysis machine.
Some of the potential benefits of the HemoStream(TM) catheter include:
- Patented Triple Arterial Lumen Design: Ensures functional flow rates
in the event that two lumens become completely occluded.
- Transition: Provides atraumatic over-the-wire insertion without the
need for a peel-away sheath.
- 360 degree Arterial Tip Configuration: Eliminates catheter "side-
walling" against vessel.
In April 2007, Angiotech entered into an agreement with Rex Medical, LP,
which granted Angiotech an exclusive license to market and distribute the
HemoStream(TM) catheter worldwide. The U.S. Food and Drug Administration (FDA)
has given clearance to begin marketing the HemoStream(TM) chronic dialysis
catheter in the United States.
Angiotech will be exhibiting in Booth No.233 at the 33rd Annual Meeting
of the Society of Interventional Radiologists to be held March 15-18th, 2008
in Washington, D.C. More information about the meeting can be found on the
Society of Interventional Radiology website at:
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,600 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP),
please visit www.angiotech.com.
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research development and product and drug development. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements. Many such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions, both nationally and in the regions in which
we operate; market demand; technological changes that could impact our
existing products or our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or the failure
to comply with, governmental regulations; adverse results or unexpected delays
in drug discovery and clinical development processes; decisions, and the
timing of decisions, made by health regulatory agencies regarding approval of
our technology and products; the requirement for substantial funding to
conduct research and development and to expand commercialization activities or
consummate acquisitions; the accuracy of our estimations of the size of the
market, and the potential market, for our products in specific disease areas;
sales numbers and future guidance publicly provided by Boston Scientific
Corporation regarding sales of their paclitaxel-eluting coronary stent
products; and any other factors that may affect performance. In addition, our
business is subject to certain operating risks that may cause the actual
results expressed or implied by the forward-looking statements in this report
to differ materially from our actual results. These operating risks include:
our ability to attract and retain qualified personnel; our ability to
successfully complete preclinical and clinical development of our products;
changes in business strategy or development plans; our failure to obtain
patent protection for discoveries; loss of patent protection resulting from
third party challenges to our patents; commercialization limitations imposed
by patents owned or controlled by third parties; our ability to obtain rights
to technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the ability of Boston Scientific
Corporation to successfully manufacture, market and sell their
paclitaxel-eluting coronary stent products; the continued availability of
capital to finance our activities; our ability to achieve the financial
benefits expected as a result of the acquisition of American Medical
Instruments Holdings, Inc. ("AMI"); and any other factors referenced in our
annual information form and other filings with the applicable Canadian
securities regulatory authorities or the SEC. Given these uncertainties,
assumptions and risk factors, readers are cautioned not to place undue
reliance on such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any revisions to
any of the forward-looking statements contained in this press release to
reflect future results, events or developments.
(TM)HemoStream is a trademark of Rex Medical, LP used under license by
For further information:
For further information: Angiotech Contact: Deirdre Neary, Angiotech
Pharmaceuticals, Inc., (604) 222-7056, email@example.com